FGF23 and myocardial infarction: We addressed whether intervention with dietary n-3 fatty acid supplementation for 41 months may reduce plasma FGF23 levels in post-myocardial infarction patients participating in the Alpha Omega Trial, a large randomized controlled trial that compared treatment with low-dose eicosapentaenoic acid-docosahexaenoic acid (EPA-DHA) or alpha-linoleic acid (ALA) supplementation with placebo [17].